Tom Roberts, B.S., M.B.A, Chief Executive Officer, Founder (San Antonio, TX). Tom has 30 years of experience in significant leadership roles and executive management at large corporations, mid-caps, and start-ups in the medical device and biotech sectors. He has held senior leadership positions at Acelity and Hoffmann-La Roche, including Head of Product Development for a billion-dollar healthcare brand. In this role, Tom led global development, regulatory clearance, and commercialization of 10+ healthcare technology products. Prior to joining VNB, Tom served as CEO/Board Director at Invictus Medical, Inc. (San Antonio, TX), a start-up healthcare technology company where he successfully raised $10M in financing as well as directed the funding, full development, regulatory clearance, and commercialization of a novel UT-licensed healthcare technology. Tom received his B.S (Biology) from Denison University and M.B.A. from Indiana Wesleyan University.
Matthew Gdovin, Ph.D., Chief Scientific Officer, Founder (San Antonio, TX). After receiving his Ph.D. in Physiology at Dartmouth College, Dr. Gdovin completed his post-doctoral fellowship at The University of Calgary Faculty of Medicine. From 1997 to 2018, he was an Assistant Professor, then Full Professor of Physiology at UTSA. During his academic tenure, Dr. Gdovin formed VNB and became its full-time Chief Scientific Officer in 2018. In this role, he helped raise $1.28M in financing, participated in the solidification of critical strategic partnerships, and led the development of VNB’s nanoparticle-based drug. Dr. Gdovin has been awarded over $3.2M by the NIH for research in physiology, respiratory control, and neurobiology. He has fostered research collaborations with the Institute for Drug Development at the Cancer Therapy and Research Center at the UT Health Science Center.
Greg Espenhover, CPA, Chief Financial Officer, Founder (San Antonio, TX) Greg is an entrepreneur and CPA with 30+ years’ experience in providing accounting, tax, and business consulting services. Since 1988, he has been a CPA under the Texas State Board of Accountancy, as well as a member of the American Institute of Certified Public Accountants and Texas Society of Certified Public Accountants and holds Certified Information Technology Professional AICPA designation. In 1999, Greg became a Shareholder and Partner with Davidson Freedle Espenhover & Overby, P.C., providing accounting, auditing, consulting, and tax services for private companies.
Harald Stock, Ph.D., Board Director and Advisor (Logan, UT). Harald is a healthcare entrepreneur, investor, board director, and serial CEO. After obtaining his Ph.D. in Inorganic Chemistry from Heidelberg University, he spent 10+ years in big pharma/medical technology at Roche and Johnson & Johnson. As a serial CEO, he was CEO of the Grünenthal Group (2009 to 2013); ArjoHuntleigh (2014); and OvaScience (NASDAQ:OVAS; 2016). Harald is Board Director at Quantum Diamond Technologies (Somerville, MA) and clinical-stage immuno-oncology company Immatics Biotechnologies (Houston, TX).